Results for renal cell carcinoma (4)

  News   FDA approves Inlyta to treat patients with a type of advanced kidney cancer
The U.S. Food and Drug Administration approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
  Leaflet Drug   Naptumomab estafenatox
Naptumomab estafenatox for the treatment of renal cell carcinoma
  News   Pfizer Files For European Regulatory Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma
Pfizer Inc. announced that the European Medicines Agency (EMA) has accepted Pfizer’s filing for regulatory review of axitinib for patients with advanced renal cell carcinoma (RCC) after failure of prior systemic treatment.
  Leaflet Drug   4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline
Renal cell carcinoma (also called cancer of the kidney or renal adenocarcinoma) is a disease in which cancer (malignant) cells are found in certain tissues of the kidney.

General Search


 Latest News

U.S. Food And Drug Administration Approves Pfizer’s INLYTA (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph Chronic Myeloid Leukemia
FDA approves Inlyta to treat patients with a type of advanced kidney cancer
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
FDA. New and Generic Drug Approvals - January 27, 2012

 Latest Drugs

Efavirenz Teva
Desloratadine Actavis
Repaglinide Accord
Emselex
Hepsera
Zulvac 1 Ovis
Zulvac 1 Bovis
Levetiracetam Sun
Inovelon
Olanzapine Glenmark Europe

 Latest Articles

Wrist Injuries and Disorders
Valley Fever
Verruca ( Warts)
Von Hippel-Lindau Disease
Vitiligo

Last medical tags:


Torisel, temsirolimus, Inlyta, chronic myeloid leukemia, bosutinib, Inlyta, renal cell carcinoma, kidney cancer, myelin, Tysabri, natalizumab, brain infection, progressive multifocal leukoencephalopathy, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, thoracic aortic transection, endovascular graft, methotrexate, Voraxaze, cancer chemotherapy drug, glucarpidase, Adcetris, bleomycin, multifocal leukoencephalopathy, CardioGen-82, radiation, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, raltegravir, Isentress, antiretroviral medicines, Theravance, Relovair, asthma, fluticasone, bronchitis, neuromuscular disease, SMA, muscle atrophy, Resolor, prokinetic, prucalopride, ADHD, psychiatric behavioural disorder, Venvanse, lisdexamfetamine dimesylate, type 2 diabetes mellitus, Actoplus Met XR, pioglitazone, Mylan, Eprosartan Mesylate Tablets, Teveten, antimicrobials, cephapirin, cephalosporin, teriflunomide, Rebif, alanine aminotransferase levels, flu-like symptoms, multiple sclerosis, electrical pulses, implantable pulse generator, Precision Plus Spinal Cord Stimulator, genetic blood clotting disorder, hemophilia A, Advate, bleeding episodes, heart failure, heart transplantation, Pediatric Medical Device Safety, pulsatile cardiac assist device, selective serotonin reuptake inhibitor, SSRI, pulmonary hypertension,
» All tags  
Sitemap